Category Archives: X-396 – ensartinib from Xcovrery

More ASCO abstracts

Posted on May 15, 2014 by admin

There is an abstract for X-396 that included 30 patients (21 NSCLC and only 13 ALK+). Maximum tolerated dose not reached. Current maximum dosage was 250mg. In the 6 ALK+ patients who received greater than or equal to 200mg, 82% … Continue reading →

Posted in Brain metastases, Lung cancer, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

List of 9 ALK Inhibitors

Posted on May 9, 2014 by admin

List of 9 ALK inhibitor drugs currently in clinical trials: FDA approved (but several trials ongoing) Novartis – Ceritinib Pfizer – Crizotinib FDA Breakthrough Status Chugai – Alectinib (filed NDA in Japan) Ongoing trials Ariad AP26113 Nerviano NMS-E628. (Licensed by … Continue reading →

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Clinical trial results to be announced at ASCO 2014 (5/30 to 6/3)

Posted on May 9, 2014 by admin

Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). (Abstract 8047) Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. … Continue reading →

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

List of drugs in clinical trials

Posted on October 20, 2013 by admin

List of 10 ALK inhibitor drugs currently (or soon to be) in clinical trials: Ariad AP26113 Astellas ASP-3026 Chugai Alectinib (filed NDA in Japan) Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101) Novartis LDK-378 Pfizer Crizotinib (FDA approved but several … Continue reading →

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, NMS-E628, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment